Wolfe Research has initiated coverage on Celcuity Inc (CELC), assigning an Outperform rating. This marks the firm's first assessment of the biotechnology company, which is headquartered in Minneapolis, Minnesota.
Celcuity operates as a cellular analysis company, focusing on innovative treatments for advanced breast and prostate cancers. Its lead therapeutic candidate, gedatolisib, selectively targets Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and mechanistic targets of rapamycin (mTOR) sub-complexes. The company is currently conducting a Phase III clinical trial, VIKTORIA-1, to evaluate gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.
As of November 17, 2025, Celcuity's stock is priced at $91.60, and the company has a market capitalization of $4.3 billion. Analysts have a consensus rating of Buy, with recent actions indicating a mixture of upgrades and downgrades, including a downgrade to Neutral by HC Wainwright on November 17, 2025.
Upcoming earnings are anticipated on August 11, 2026, with earnings per share (EPS) estimated at -$1.15 and revenue expected to reach $765,000. Analyst ratings can fluctuate over time as new data emerges, making it essential for investors to consider a range of factors when evaluating investment opportunities.
This brief was generated from structured financial data and reviewed by the Investing Point editorial team. It is for informational purposes only and does not constitute investment advice.